The United Kingdom left the European Union on 31 January and is now in a Transition Period until 31 December 2020. During this time, it remains our objective to negotiate a future relationship with the EU and in our respective published negotiating documents, we have both stated objectives to reach an agreement on trade in goods. The UK\u2019s published approach sets out how we want to facilitate trade in medicinal products and support high levels of patient safety.<\/p>
The Government, pharmaceutical industry and National Health Service will always work closely together to help ensure patients continue to have access, to the medicines and treatments they need, including insulin, under all scenarios.<\/p>
The Department has well-established procedures to deal with medicine shortages and is working closely with industry, the NHS and others in the supply chain to reduce the likelihood of future shortages resulting from any cause.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4708", "label" : {"_value" : "Biography information for Lord Bethell"} } , "answeringMemberPrinted" : {"_value" : "Lord Bethell"} , "dateOfAnswer" : {"_value" : "2020-06-30", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL5713"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-06-30T15:47:39.5Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-06-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "Her Majesty's Government what assessment they have made about whether any drugs or medicines will be in short supply after the UK leaves the EU.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3691", "label" : {"_value" : "Biography information for Lord Roberts of Llandudno"} } , "tablingMemberPrinted" : [{"_value" : "Lord Roberts of Llandudno"} ], "uin" : "HL5715"} , {"_about" : "http://data.parliament.uk/resources/1186624", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1186624/answer", "answerText" : {"_value" : "
The Government has no plans to create facilities in the United Kingdom to manufacture further active pharmaceutical ingredients. There are 16,000 medicines on the market in the UK. Whilst some of these are manufactured in the UK, most are manufactured abroad. Where medicines are manufactured here, the active ingredients and excipients for those medicines may be manufactured abroad. It is not realistic to manufacture all 16,000 medicines and the active ingredients and excipients needed for these medicines in the UK.<\/p>
The production of medicines is complex and highly regulated, and materials and processes must meet rigorous safety and quality standards. Supply problems can affect a wide range of medicines and can arise for various reasons, such as manufacturing issues, problems with the raw ingredients and batch failures. These problems arise regardless of where in the world the manufacture takes place.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2020-04-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1186624/answer/previousversion/14443", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} } , "questionFirstAnswered" : [{"_value" : "2020-04-14T14:50:24.04Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-03-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to manufacture more active pharmaceutical ingredients in the UK to prevent medicine shortages.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4779", "label" : {"_value" : "Biography information for Taiwo Owatemi"} } , "tablingMemberConstituency" : {"_value" : "Coventry North West"} , "tablingMemberPrinted" : [{"_value" : "Taiwo Owatemi"} ], "uin" : "32261"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 2, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }